Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer ...